Novo Nordisk’s Q2 2025 results showed resilient revenue growth, but profit guidance was cut due to U.S. competition, compounded drugs, and currency headwinds. I see the upcoming Q3 earnings and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback